C. Sander

发表

Genomic Classification of Cutaneous Melanoma

Steven J. M. Jones, Martin L. Miller, Jared C Malke, 2015, Cell.

Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma.

Y. Najjar, J. Kirkwood, Ashley V. Menk, 2019, JCI insight.

Predicting Metastasis in Melanoma by Enumerating Circulating Tumor Cells Using Photoacoustic Flow Cytometry

Robert H Edgar, C. Sander, Robert H. Edgar, 2020, Lasers in surgery and medicine.

T Cells Induced by Melanoma Vaccines + CD 8 Specific − PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

Microenvironment and Immunology PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen – Speci fi c CD 8 þ T Cells Induced by Melanoma Vaccines

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, 2013, Cancer research.

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells

J. Kirkwood, J. Hancock, P. Dent, 2019, Cancer biology & therapy.

Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy

T. Ideker, S. Chanda, R. Dummer, 2015, Oncogene.

Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit

W. LaFramboise, C. Sander, Hui-Min Lin, 2017, Oncoimmunology.

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-&agr;2b in patients with metastatic melanoma

J. Kirkwood, S. Moschos, C. Sander, 2017, Melanoma research.

Indoor tanning exposure in association with multiple primary melanoma

Hong Wang, J. Kirkwood, C. Sander, 2020, Cancer.

Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696

J. Kirkwood, L. Butterfield, T. Whiteside, 2009, Clinical Cancer Research.

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

Simon C Watkins, D. Davar, Joe-Marc Chauvin, 2022, The Journal of clinical investigation.

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi

Amy Rose, J. Kirkwood, H. Zarour, 2018, Cancer Prevention Research.

Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients

J. Kirkwood, H. Zarour, A. Donnenberg, 2008, Journal of immunotherapy.

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

J. Kirkwood, L. Butterfield, C. Sander, 2015, Journal of Immunotherapy for Cancer.

PatientsT Cell Expansion in Melanoma PD-1 Is a Regulator of NY-ESO-1-Specific

J. Kirkwood, C. Sander, S. Land, 2013 .

PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1

J. Kirkwood, H. Zarour, S. Ferrone, 2009, The Journal of Immunology.

Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors

Simon C Watkins, J. Kirkwood, L. Butterfield, 2022, Journal of translational medicine.

Multiple primary melanoma in association with other personal and familial cancers

J. Kirkwood, C. Sander, Ziyu Huang, 2022, Cancer medicine.

TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma

Holly C. Beale, C. Connelly, J. Kirkwood, 2022, Science.

Poorer survival outcomes in patients with multiple versus single primary melanoma

Hong Wang, J. Kirkwood, C. Sander, 2022, Cancer.

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696

J. Kirkwood, C. Sander, A. Tarhini, 2007 .

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.

J. Kirkwood, C. Sander, A. Tarhini, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

J. Kirkwood, H. Zarour, V. Kuchroo, 2010, The Journal of experimental medicine.

Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity

J. Kirkwood, R. Ferris, J. Kolls, 2017, Cell.

An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

H. Rui, J. Kirkwood, P. Lehner, 2019, Cancer cell.

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients

S. Ringquist, L. Butterfield, H. Gogas, 2015, PloS one.

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015, The Journal of clinical investigation.

CD56dim CD16− Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α

Patricia M. Santos, Afshin Mashadi-Hossein, J. Kirkwood, 2019, Front. Immunol..

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma

J. Kirkwood, W. LaFramboise, U. Rao, 2017, Melanoma research.

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

J. Kirkwood, H. Tawbi, L. Butterfield, 2014, PloS one.

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

J. Kirkwood, H. Tawbi, S. Moschos, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitotic Arrest, Apoptosis, and Sensitization to Chemotherapy of Melanomas by Methionine Deprivation Stress

J. Kirkwood, S. Chada, D. Bocangel, 2006, Molecular Cancer Research.

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo

J. Kirkwood, P. Dent, C. Sander, 2017, Oncotarget.

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

Ornella Pagliano, J. Kirkwood, H. Zarour, 2012, Cancer research.

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

J. Kirkwood, P. Dent, C. Sander, 2017, Cancer biology & therapy.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Mitochondrial Respiration - An Important Therapeutic Target in Melanoma

J. Kirkwood, T. Conrads, B. Van Houten, 2012, PloS one.

A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma

J. Kirkwood, W. LaFramboise, C. Sander, 2014, Journal of Translational Medicine.

Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma

J. Kirkwood, S. Moschos, C. Sander, 2012, Journal of immunotherapy.

Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

J. Kim, D. Davar, Amy Rose, 2021, Clinical Cancer Research.

Microenvironment and Immunology CD 8 þ T Cells Speci fi c for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

Ornella Pagliano, J. Kirkwood, H. Zarour, 2012 .

Development and Narrow Validation of Computer Vision Approach to Facilitate Assessment of Change in Pigmented Cutaneous Lesions

Paul H. Haley, Ellen K. Hughes, Hong Wang, 2023, JID innovations : skin science from molecules to population health.

Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma

J. Kirkwood, C. Sander, M. Panelli, 2022, Cancers.

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Joe-Marc Chauvin, Ornella Pagliano, J. Kirkwood, 2015, Cancer research.

IL 10 and PD-1 Cooperate to Limit the Activity of Tumor-Speci fi c CD 8 þ T Cells

Joe-Marc Chauvin, Ornella Pagliano, J. Kirkwood, 2015 .

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

D. Davar, J. Kirkwood, H. Tawbi, 2017, Journal of Immunotherapy for Cancer.

Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa

J. Kirkwood, C. Sander, Donghoon Shin, 2014, Melanoma research.

CD226 opposes TIGIT to disrupt Tregs in melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, JCI insight.

Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs

E. Puré, T. Mak, J. Kirkwood, 2020, Nature Cancer.

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma

J. Kirkwood, J. Yearley, U. Rao, 2015, Journal of Translational Medicine.

Pharmacodynamic (Phase 0) Study Using Etaracizumab in Advanced Melanoma

Manuela Buzoianu, Charalambos Athanassiou, Drazen M Jukic, 2010, Journal of immunotherapy.

Phase IB study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL).

D. Davar, Joe-Marc Chauvin, Ornella Pagliano, 2016 .

Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study

D. Davar, Y. Najjar, J. Kirkwood, 2023, Frontiers in oncology.

Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients.

J. Kirkwood, L. Butterfield, C. Sander, 2012, Journal of immunological methods.

High-dose interleukin-2 (HD IL-2) in the treatment of advanced melanoma: The University of Pittsburgh experience.

D. Davar, J. Kirkwood, H. Tawbi, 2013 .

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma

J. Kirkwood, J. Yearley, U. Rao, 2015, Journal of Translational Medicine.

E1696: Final analysis of the clinical and immunological results of a multicenter ECOG phase II trial of multi-epitope peptide vaccination for stage IV melanoma with MART-1 (27-35), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) (MGT) +/- IFN{alpha}2b and GM-CSF

J. Kirkwood, T. Whiteside, L. Weiner, 2004 .

Targeting PD-1 and Tim-3 pathways to reverse tumor antigen-specific CD4+ T cell dysfunction in patients with advanced melanoma (66.1)

J. Kirkwood, H. Zarour, V. Kuchroo, 2011, Journal of Immunology.

Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes

D. Davar, Y. Najjar, J. Kirkwood, 2023, Frontiers in Immunology.

Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.

J. Kirkwood, H. Tawbi, S. Moschos, 2010 .

Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015 .

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma

D. Davar, Y. Najjar, J. Kirkwood, 2023, bioRxiv.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma

J. Kirkwood, S. Moschos, C. Sander, 2012, Journal of immunotherapy.